ArticleCureus2026
Clinicopathological Correlation of Kidney Allograft Biopsies According to the Banff 2022 Classification.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Kidney allograft biopsy remains the gold standard for the diagnosis of allograft dysfunction, providing essential information for identifying immune- and non-immune-mediated injuries. The Banff 2022 Classification represents the current international standard for the histopathological evaluation of kidney transplant biopsies. This study aimed to describe the clinicopathological distribution of kidney allograft biopsies according to the Banff 2022 Classification and to assess graft function 12 months after the index biopsy. Methods A retrospective descriptive study was conducted involving 119 kidney transplant recipients who underwent kidney allograft biopsy at Hospital Hermanos Ameijeiras, Havana, Cuba, between January 2006 and December 2018. Archived biopsy specimens were re-evaluated by an experienced renal pathologist according to the Banff 2022 Classification. Demographic characteristics, histopathological diagnoses, time from transplantation to biopsy, and graft function 12 months after the index biopsy were analyzed using descriptive statistics. Graft function was assessed by estimated glomerular filtration rate (eGFR) and proteinuria. Results Male recipients and patients younger than 60 years predominated in the study population. Non-rejection causes of allograft injury represented the largest diagnostic group, accounting for 52 (43.7%) biopsies, followed by T cell-mediated rejection (TCMR) in 37 (31.1%) and antibody-mediated rejection (ABMR) in 14 (11.8%). Histopathological diagnoses exhibited distinct temporal patterns after transplantation. During the first three months, acute cyclosporine nephrotoxicity was the most frequent diagnosis, followed by acute tubular necrosis (ATN) and acute TCMR, whereas after the first post-transplant year, chronic active TCMR was the most frequent diagnosis, followed by chronic active antibody-mediated rejection and chronic cyclosporine nephrotoxicity. At 12 months after the index biopsy, immune-mediated lesions generally showed lower mean eGFR values and more frequent proteinuria, whereas normal biopsies and non-immunological lesions, particularly ATN and acute cyclosporine nephrotoxicity, showed comparatively better graft function. Conclusions Kidney allograft biopsies demonstrated a broad spectrum of histopathological diagnoses, with non-rejection causes of allograft injury representing the most frequent findings. Histopathological diagnoses showed distinct temporal patterns according to the time from transplantation to biopsy, with acute cyclosporine nephrotoxicity predominating during the first three months after transplantation. At 12 months after the index biopsy, immune-mediated lesions generally showed lower eGFR and more frequent proteinuria, whereas normal biopsies and non-immune-mediated lesions showed comparatively better graft function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.